Why did OXUR.BR stock drop pre-market today?

OXUR.BR stock fell **16.67%** pre-market on 25 Mar 2026 due to thin liquidity, higher-than-average selling and positioning ahead of an earnings release on 03 Apr 2026. Micro-cap biotech volatility often amplifies such moves.

What are the main risks for OXUR.BR stock investors?

Main risks include clinical trial setbacks, rapid dilution from new financing, very low liquidity (market cap **€350492.00**) and weak short-term solvency (current ratio **0.17**), all of which can cause abrupt price swings.

Does Meyka AI give a price forecast for OXUR.BR stock?

Meyka AI's forecast model projects a yearly value **€320.61** (model-based). We also outline scenario targets: conservative **€0.01**, base **€0.02**, aggressive **€0.05**. Forecasts are projections, not guarantees.

When is the next catalyst for OXUR.BR stock?

The next scheduled catalyst is Oxurion's earnings announcement on **03 Apr 2026**. Clinical updates on THR-149 or THR-687 could also move the stock sooner.

EU Stocks

OXUR.BR Oxurion NV (EURONEXT) down 16.67% pre-market to €0.005 25 Mar 2026: watch April earnings

ByHuzaifa Zahoor March 25, 2026March 25, 2026

OXUR.BR stock plunged 16.67% pre-market to €0.005 on 25 Mar 2026 after heavy selling on EURONEXT, making it one of this session’s top losers. Trading volume hit 351105.00 shares versus a 50-day average of 360193.00, signaling active repositioning ahead of an earnings announcement on 03 Apr 2026. Investors should note the tiny market cap of €350492.00 and very low liquidity, which amplify volatility and execution risk for trades.